These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3217461)

  • 21. Cortisol response to clonidine in panic disorder: comparison with depressed patients and normal controls.
    Stein MB; Uhde TW
    Biol Psychiatry; 1988 Jul; 24(3):322-30. PubMed ID: 2840978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential 3H-imipramine platelet binding in patients with panic disorder and depression.
    Innis RB; Charney DS; Heninger GR
    Psychiatry Res; 1987 May; 21(1):33-41. PubMed ID: 3037580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-HT2C receptor mediation of unconditioned escape behaviour in the unstable elevated exposed plus maze.
    Jones N; Duxon MS; King SM
    Psychopharmacology (Berl); 2002 Nov; 164(2):214-20. PubMed ID: 12404085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time courses of behavioral and regional cerebral metabolic responses to different doses of meta-chlorophenylpiperazine in awake rats.
    Freo U; Soncrant TT; Ricchieri GL; Wozniak KM; Larson DM; Rapoport SI
    Brain Res; 1990 Mar; 511(2):209-16. PubMed ID: 2334843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comorbidity of panic disorder and major depressive disorder: effects on platelet alpha 2 adrenergic receptors.
    Grunhaus LJ; Cameron O; Pande AC; Haskett RF; Hollingsworth PJ; Smith CB
    Acta Psychiatr Scand; 1990 Mar; 81(3):216-9. PubMed ID: 2160772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of m-chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects.
    Kahn RS; Knott P; Gabriel S; DuMont K; Mastroianni L; Davidson M
    Biol Psychiatry; 1992 Dec; 32(11):1055-61. PubMed ID: 1467386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonin and panic disorders: a review of clinical studies.
    Norman TR; Burrows GD; Judd FK; McIntyre IM
    Int J Clin Pharmacol Res; 1989; 9(2):151-7. PubMed ID: 2654037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of selective tolerance to the serotonin behavioral syndrome and suppression of locomotor activity after repeated administration of either 5-MeODMT or mCPP.
    Sills MA; Lucki I; Frazer A
    Life Sci; 1985 Jul; 36(26):2463-9. PubMed ID: 4010463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects.
    Kahn RS; Siever LJ; Gabriel S; Amin F; Stern RG; DuMont K; Apter S; Davidson M
    Psychiatry Res; 1992 Jul; 43(1):1-12. PubMed ID: 1332094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serotonin function in panic disorder: effect of 1-5-hydroxytryptophan in patients and controls.
    Westenberg HG; den Boer JA
    Psychopharmacology (Berl); 1989; 98(2):283-5. PubMed ID: 2526957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats.
    Jenck F; Martin JR; Moreau JL
    J Psychopharmacol; 1999; 13(2):166-70. PubMed ID: 10475723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
    Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
    Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seasonal variation in behavioral responses to m-CPP in patients with seasonal affective disorder and controls.
    Joseph-Vanderpool JR; Jacobsen FM; Murphy DL; Hill JL; Rosenthal NE
    Biol Psychiatry; 1993 Apr; 33(7):496-504. PubMed ID: 8390305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder.
    Broocks A; Bandelow B; George A; Jestrabeck C; Opitz M; Bartmann U; Gleiter CH; Meineke I; Roed IS; Rüther E; Hajak G
    Int Clin Psychopharmacol; 2000 May; 15(3):153-61. PubMed ID: 10870873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serotonergic sensitivity in borderline personality disorder: preliminary findings.
    Hollander E; Stein DJ; DeCaria CM; Cohen L; Saoud JB; Skodol AE; Kellman D; Rosnick L; Oldham JM
    Am J Psychiatry; 1994 Feb; 151(2):277-80. PubMed ID: 8296905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allelic variants of the serotonin(2C) receptor and neuroendocrinological responses to the serotonin(2C) receptor agonist m-chlorophenylpiperazine in healthy male volunteers.
    Kühn KU; Quednow BB; Bagli M; Meyer K; Feuchtl A; Westheide J; Frahnert C; Maier W; Rao ML
    Pharmacopsychiatry; 2002 Nov; 35(6):226-30. PubMed ID: 12518270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of anxiogenic vulnerability in panic disorder.
    Targum SD
    Psychiatry Res; 1990 Feb; 31(2):215-6. PubMed ID: 2326400
    [No Abstract]   [Full Text] [Related]  

  • 38. Prolactin and sodium lactate-induced panic.
    Hollander E; Liebowitz MR; Cohen B; Gorman JM; Fyer AJ; Papp LA; Klein DF
    Psychiatry Res; 1989 May; 28(2):181-91. PubMed ID: 2748770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. m-Chlorophenylpiperazine as a probe of serotonin function.
    Kahn RS; Wetzler S
    Biol Psychiatry; 1991 Dec; 30(11):1139-66. PubMed ID: 1663792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa.
    Levitan RD; Kaplan AS; Joffe RT; Levitt AJ; Brown GM
    Arch Gen Psychiatry; 1997 Jun; 54(6):521-7. PubMed ID: 9193192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.